Skip to main content
. 2013 Jun 16;15(6):577–589. doi: 10.1007/s10198-013-0495-y

Fig. 5.

Fig. 5

Level of additional benefit (%) in 40 assessed patient subgroups in the 23 evaluated EBAs (23 of 31 drugs, 4 drugs exempted and 4 without submitted dossier)